As part of a new initiative centered on the COVID-19 vaccine rollout and the needs of the Duchenne community, CureDuchenne is hosting the following webinar on January 22: “COVID-19 Vaccines – What the Duchenne Community Needs to Know.”

A roster of panelists will include a “who’s who” in COVID-19 vaccine development organizations and from American regulatory bodies, according to CureDuchenne:

  • Peter Marks, MD, PhD, Director of FDA Center for Biologics Evaluation and Research
  • Georgina Peacock, MD, MPH, FAAP, Director of Division of Human Development and Disability, CDC National Center on Birth Defects and Developmental Disabilities
  • William Gruber, MD, Senior Vice President, Vaccine Clinical Research and Development, Pfizer, Inc.
  • Oscar “Hank” Mayer, MD, Director of Pulmonary Function Laboratory, Children’s Hospital of Philadelphia 
  • Kathy Mathews, MD, Professor of Pediatrics and Neurology, Vice Chair for Clinical Investigation, Department of Pediatrics, University of Iowa
  • Debra Miller, Founder and CEO, CureDuchenne
  • Moderated by: Michael Kelly, Chief Scientific Advisor, CureDuchenne

The initiative aims to prioritize the needs of the Duchenne muscular dystrophy community for the COVID-19 vaccine rollout. Its website includes a COVID-19 webpage featuring COVID-19 vaccination resources. Also as part of the initiative, CureDuchenne submitted a comment letter to the Advisory Committee on Immunization Practices (ACIP) advocating that all Duchenne patients within the approved age groups be prioritized to get the COVID-19 vaccine.

“We are a leading voice for the Duchenne community and steadfast in our commitment to support and educate on anything related to COVID-19, including the vaccine. Our team worked tirelessly to develop a suite of support tools that educate and inform our community with the facts that matter to them the most. As we work with states and local officials, we look forward to advocating on behalf of the entire Duchenne community while the vaccine rollout progresses. Our goal is to inoculate everyone affected by Duchenne.”

— Debra Miller, founder and CEO, CureDuchenne

The webinar will be available to download at CureDuchenne after the event takes place.

[Source(s): CureDuchenne, PR Newswire]

Related Content:
COVID-19 Vaccine for the Neuromuscular Disease Community Questions Answered Here